# Ricard Ferrer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ricard-ferrer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,844 |
| Field | Sepsis Diagnosis and Treatment |
| h-index | 70 |
| i10-index | 263 |
| Last Known Institution | Universitat Autònoma de Barcelona |
| OpenAlex ID | https://openalex.org/A5033820862 |
| ORCID iD | https://orcid.org/0000-0002-4859-4747 |
| Works | 545 |

## Researcher papers

- [Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016](https://scholariq.org/papers/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and/)
- [Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021](https://scholariq.org/papers/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-3/)
- [Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016](https://scholariq.org/papers/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-2/)
- [Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021](https://scholariq.org/papers/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-4/)
- [Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-cefiderocol-or-best-available-therapy-for-the-treatment/)
- [Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021](https://scholariq.org/papers/executive-summary-surviving-sepsis-campaign-international-guidelines-for-the/)
- [Update of the treatment of nosocomial pneumonia in the ICU](https://scholariq.org/papers/update-of-the-treatment-of-nosocomial-pneumonia-in-the-icu/)
- [Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial](https://scholariq.org/papers/rezafungin-versus-caspofungin-for-treatment-of-candidaemia-and-invasive/)

## Researcher topics

- [Sepsis Diagnosis and Treatment](https://scholariq.org/topics/sepsis-diagnosis-and-treatment/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Nosocomial Infections in ICU](https://scholariq.org/topics/nosocomial-infections-in-icu/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Intensive Care Unit Cognitive Disorders](https://scholariq.org/topics/intensive-care-unit-cognitive-disorders/)

## Researcher university

- [Universitat Autònoma de Barcelona](https://scholariq.org/institutions/universitat-autonoma-de-barcelona/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.